$103.13+0.24%Close 17 Nov 2026 · Market value $132.2B · Next results 24 Nov 2026
In its results release of 1 Sep 2026 (Q1 FY2027), Medtronic plc gave 1 forecast in figures, among them EPS (adjusted) of $5.94 to $6.00 for FY2027.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q1 FY2027 results, 1 Sep 2026
| Measure | Period | Guidance | As stated |
|---|
| EPS · Adjusted · Raised | FY2027 | $5.94 to $6.00 | Raising FY27 organic revenue growth guidance 50 basis points to 7.25% to 7.75%, and FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00 |
|---|
Source: the company's earnings release.
Guidance against results last two years
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Organic revenue growth | FY2027 | +6.75% to +7.25% | Given once | — | To come |
|---|
| EPS · Adjusted | FY2027 | $5.94 to $6.00 | Raised once | — | To come |
|---|
| EPS growth · Adjusted | FY2027 | +6.7% to +8.5% | Given once | — | To come |
|---|
| Revenue growth | FY2026 | +6.5% to +6.8% | Raised once | +8.43% | Above the range |
|---|
| Revenue growth | FY2025 | +3.4% to +3.8% | Lowered once | +3.62% | Within the range |
|---|
MDT in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.